Luis Alvarez-Vallina

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/8642853/publications.pdf

Version: 2024-02-01

101 papers	3,377 citations	172386 29 h-index	168321 53 g-index
103 all docs	103 docs citations	103 times ranked	4544 citing authors

#	Article	IF	Citations
1	Trispecific T-cell engagers for dual tumor-targeting of colorectal cancer. OncoImmunology, 2022, 11, 2034355.	2.1	21
2	Overcoming CAR-Mediated CD19 Downmodulation and Leukemia Relapse with T Lymphocytes Secreting Anti-CD19 T-cell Engagers. Cancer Immunology Research, 2022, 10, 498-511.	1.6	12
3	Synapse topology and downmodulation events determine the functional outcome of anti-CD19 T cell-redirecting strategies. OncoImmunology, 2022, 11, 2054106.	2.1	7
4	Applications of trimerbodies in cancer immunotherapy. International Review of Cell and Molecular Biology, 2022, , 71-87.	1.6	0
5	An Fc-free EGFR-specific 4-1BB-agonistic Trimerbody Displays Broad Antitumor Activity in Humanized Murine Cancer Models without Toxicity. Clinical Cancer Research, 2021, 27, 3167-3177.	3.2	16
6	Programmable half-life and anti-tumour effects of bispecific T-cell engager-albumin fusions with tuned FcRn affinity. Communications Biology, 2021, 4, 310.	2.0	29
7	Bispecific Immunomodulatory Antibodies for Cancer Immunotherapy. Clinical Cancer Research, 2021, 27, 5457-5464.	3.2	59
8	P32-specific CAR T cells with dual antitumor and antiangiogenic therapeutic potential in gliomas. Nature Communications, 2021, 12, 3615.	5.8	25
9	Engineered mRNA and the Rise of Next-Generation Antibodies. Antibodies, 2021, 10, 37.	1.2	8
10	TGFâ€Î²â€induced IGFBPâ€3 is a key paracrine factor from activated pericytes that promotes colorectal cancer cell migration and invasion. Molecular Oncology, 2020, 14, 2609-2628.	2.1	18
11	Perforin gene variant A91V in young patients with severe COVID-19.. Haematologica, 2020, 105, 2844-2846.	1.7	16
12	Engineering Immune Cells for in vivo Secretion of Tumor-Specific T Cell-Redirecting Bispecific Antibodies. Frontiers in Immunology, 2020, 11, 1792.	2.2	14
13	Synthetic TILs: Engineered Tumor-Infiltrating Lymphocytes With Improved Therapeutic Potential. Frontiers in Oncology, 2020, 10, 593848.	1.3	12
14	Case Report: An EGFR-Targeted 4-1BB-agonistic Trimerbody Does Not Induce Hepatotoxicity in Transgenic Mice With Liver Expression of Human EGFR. Frontiers in Immunology, 2020, 11, 614363.	2.2	5
15	Carcinoembryonic Antigen (CEA)-Specific 4-1BB-Costimulation Induced by CEA-Targeted 4-1BB-Agonistic Trimerbodies. Frontiers in Immunology, 2019, 10, 1791.	2.2	19
16	The correlation between immune subtypes and consensus molecular subtypes in colorectal cancer identifies novel tumour microenvironment profiles, with prognostic and therapeutic implications. European Journal of Cancer, 2019, 123, 118-129.	1.3	50
17	A novel Carcinoembryonic Antigen (CEA)-Targeted Trimeric Immunotoxin shows significantly enhanced Antitumor Activity in Human Colorectal Cancer Xenografts. Scientific Reports, 2019, 9, 11680.	1.6	25
18	Immuno-PET Imaging and Pharmacokinetics of an Anti-CEA scFv-based Trimerbody and Its Monomeric Counterpart in Human Gastric Carcinoma-Bearing Mice. Molecular Pharmaceutics, 2019, 16, 1025-1035.	2.3	21

#	Article	IF	Citations
19	T Cell-Redirecting Strategies to â€˜STAbâ€™ Tumors: Beyond CARs and Bispecific Antibodies. Trends in Immunology, 2019, 40, 243-257.	2.9	32
20	Understanding the Spatial Topology of Artificial Immunological Synapses Assembled in T Cell-Redirecting Strategies: A Major Issue in Cancer Immunotherapy. Frontiers in Cell and Developmental Biology, 2019, 7, 370.	1.8	25
21	ATTACK, a novel bispecific T cell-recruiting antibody with trivalent EGFR binding and monovalent CD3 binding for cancer immunotherapy. OncoImmunology, 2018, 7, e1377874.	2.1	56
22	A tumor-targeted trimeric 4-1BB-agonistic antibody induces potent anti-tumor immunity without systemic toxicity. Nature Communications, 2018, 9, 4809.	5.8	116
23	Bispecific light T-cell engagers for gene-based immunotherapy of epidermal growth factor receptor (EGFR)-positive malignancies. Cancer Immunology, Immunotherapy, 2018, 67, 1251-1260.	2.0	20
24	Balanced secretion of anti-CEA Ã— anti-CD3 diabody chains using the 2A self-cleaving peptide maximizes diabody assembly and tumor-specific cytotoxicity. Gene Therapy, 2017, 24, 208-214.	2.3	14
25	Immune Regulation by Pericytes: Modulating Innate and Adaptive Immunity. Frontiers in Immunology, 2016, 7, 480.	2.2	108
26	Role of nucleotideâ€binding oligomerization domain 1 (<scp>NOD</scp>1) in pericyteâ€mediated vascular inflammation. Journal of Cellular and Molecular Medicine, 2016, 20, 980-986.	1.6	22
27	Efficacy and toxicity management of CAR-T-cell immunotherapy: a matter of responsiveness control or tumour-specificity?. Biochemical Society Transactions, 2016, 44, 406-411.	1.6	18
28	Intramolecular trimerization, a novel strategy for making multispecific antibodies with controlled orientation of the antigen binding domains. Scientific Reports, 2016, 6, 28643.	1.6	26
29	Bacterial secretion of soluble and functional trivalent scFv-based N-terminal trimerbodies. AMB Express, 2015, 5, 137.	1.4	2
30	The coming of age of engineered multivalent antibodies. Drug Discovery Today, 2015, 20, 588-594.	3.2	114
31	Selection strategies for anticancer antibody discovery: searching off the beaten path. Trends in Biotechnology, 2015, 33, 292-301.	4.9	29
32	In vivo secretion of anti-CD3 Ã— anti-tumor bispecific antibodies by gene-modified cells: over a decade of T-cell engagement. Molecular Therapy, 2015, 23, 612-613.	3.7	0
33	Microencapsulation of therapeutic bispecific antibodies producing cells: immunotherapeutic organoids for cancer management. Journal of Drug Targeting, 2015, 23, 170-179.	2.1	24
34	Programming Controlled Adhesion of E. coli to Target Surfaces, Cells, and Tumors with Synthetic Adhesins. ACS Synthetic Biology, 2015, 4, 463-473.	1.9	133
35	Functional comparison of single-chain and two-chain anti-CD3-based bispecific antibodies in gene immunotherapy applications. OncoImmunology, 2014, 3, e28810.	2.1	30
36	Lipopolysaccharide Activates Toll-like Receptor 4 (TLR4)-mediated NF-ÎºB Signaling Pathway and Proinflammatory Response in Human Pericytes. Journal of Biological Chemistry, 2014, 289, 2457-2468.	1.6	227

#	Article	IF	Citations
37	Efficient production of single-chain fragment variable-based N-terminal trimerbodies in Pichia pastoris. Microbial Cell Factories, 2014, 13, 116.	1.9	12
38	CientÃficos espaÃ±oles con los Dres. Greg Winter y Richard A. Lerner, premios PrÃncipe de Asturias en InvestigaciÃ³n CientÃfica y TÃ©cnica 2012. Inmunologia (Barcelona, Spain: 1987), 2013, 32, 70-74.	0.1	0
39	Gene expression profiling identifies EPHB4 as a potential predictive biomarker in colorectal cancer patients treated with bevacizumab. Medical Oncology, 2013, 30, 572.	1.2	21
40	The Efficacy Versus Toxicity Profile of Combination Virotherapy and TLR Immunotherapy Highlights the Danger of Administering TLR Agonists to Oncolytic Virus-treated Mice. Molecular Therapy, 2013, 21, 348-357.	3.7	33
41	In Vivo Secretion of Bispecific Antibodies Recruiting Lymphocytic Effector Cells. Antibodies, 2013, 2, 415-425.	1.2	1
42	Proteasome activator complex PA28 identified as an accessible target in prostate cancer by in vivo selection of human antibodies. Proceedings of the National Academy of Sciences of the United States of America, 2013, 110, 13791-13796.	3.3	26
43	Immunotherapeutic organoids. Biomatter, 2013, 3, e23897.	2.6	9
44	Generation and characterization of monospecific and bispecific hexavalent trimerbodies. MAbs, 2013, 5, 70-79.	2.6	30
45	CARbodies: Human Antibodies Against Cell Surface Tumor Antigens Selected From Repertoires Displayed on T Cell Chimeric Antigen Receptors. Molecular Therapy - Nucleic Acids, 2013, 2, e93.	2.3	30
46	Antibody Gene Therapy: Getting Closer to Clinical Application?. Current Gene Therapy, 2013, 13, 282-290.	0.9	21
47	Basement Membrane-Rich Organoids with Functional Human Blood Vessels Are Permissive Niches for Human Breast Cancer Metastasis. PLoS ONE, 2013, 8, e72957.	1.1	15
48	In vivo selection of tumor-specific antibodies. Oncotarget, 2013, 4, 1547-1547.	0.8	3
49	Improved stability of multivalent antibodies containing the human collagen XV trimerization domain. MAbs, 2012, 4, 226-232.	2.6	27
50	Virotherapy, gene transfer and immunostimulatory monoclonal antibodies. OncoImmunology, 2012, 1, 1344-1354.	2.1	8
51	Dr. Gregory Winter y Dr. Richard A. Lerner, Premios PrÃncipe de Asturias de InvestigaciÃ³n CientÃfica y TÃ©cnica 2012. Inmunologia (Barcelona, Spain: 1987), 2012, 31, 127-134.	0.1	0
52	The Heterotrimeric Laminin Coiled-Coil Domain Exerts Anti-Adhesive Effects and Induces a Pro-Invasive Phenotype. PLoS ONE, 2012, 7, e39097.	1.1	8
53	Non-hematopoietic stem cells as factories for in vivo therapeutic protein production. Gene Therapy, 2012, 19, 1-7.	2.3	19
54	The axonal repellent Slit2 inhibits pericyte migration: Potential implications in angiogenesis. Experimental Cell Research, 2012, 318, 371-378.	1.2	34

#	Article	IF	Citations
55	The therapeutic potential of engineered human neovessels for cell-based gene therapy. Expert Opinion on Biological Therapy, 2011, 11, 67-76.	1.4	5
56	New trends in immunotherapy. Inmunologia (Barcelona, Spain: 1987), 2011, 30, 128-134.	0.1	0
57	Engineered human tumor xenografts with functional human vascular networks. Microvascular Research, 2011, 81, 18-25.	1.1	9
58	Engineering human cells for in vivo secretion of antibody and non-antibody therapeutic proteins. Current Opinion in Biotechnology, 2011, 22, 924-930.	3.3	15
59	The Multicompartmental p32/gClqR as a New Target for Antibody-based Tumor Targeting Strategies. Journal of Biological Chemistry, 2011, 286, 5197-5203.	1.6	40
60	The multicompartmental p32/gClqR as a new target for antibody-based tumor targeting strategies.. Journal of Biological Chemistry, 2011, 286, 22706.	1.6	1
61	Multivalent antibodies: when design surpasses evolution. Trends in Biotechnology, 2010, 28, 355-362.	4.9	172
62	Factory neovessels: engineered human blood vessels secreting therapeutic proteins as a new drug delivery system. Gene Therapy, 2010, 17, 745-751.	2.3	25
63	In Vivo Tumor Targeting and Imaging with Engineered Trivalent Antibody Fragments Containing Collagen-Derived Sequences. PLoS ONE, 2009, 4, e5381.	1.1	56
64	Lymphocyte Display: A Novel Antibody Selection Platform Based on T Cell Activation. PLoS ONE, 2009, 4, e7174.	1.1	16
65	Differential transplantability of human endothelial cells in colorectal cancer and renal cell carcinoma primary xenografts. Laboratory Investigation, 2009, 89, 91-97.	1.7	32
66	Tumor Immunotherapy Using Gene-Modified Human Mesenchymal Stem Cells Loaded into Synthetic Extracellular Matrix Scaffolds. Stem Cells, 2009, 27, 753-760.	1.4	89
67	Functionally fused antibodiesâ€"A novel adjuvant fusion system. Journal of Immunological Methods, 2008, 339, 220-227.	0.6	0
68	Long-term in vivo imaging of human angiogenesis: Critical role of bone marrow-derived mesenchymal stem cells for the generation of durable blood vessels. Microvascular Research, 2008, 75, 308-314.	1.1	77
69	Comment on â€œProduction of multivalent protein binders using a selfâ€trimerization collagenâ€like peptide scaffoldâ€• FASEB Journal, 2008, 22, 3417-3417.	0.2	0
70	Inhibition of tumor growth in vivo by in situ secretion of bispecific anti-CEA Ã— anti-CD3 diabodies from lentivirally transduced human lymphocytes. Cancer Gene Therapy, 2007, 14, 380-388.	2.2	60
71	Enhancement of DNA vaccine potency through linkage of antigen to filamentous bacteriophage coat protein III domain I. Immunology, 2006, 117, 502-506.	2.0	15
72	Enhanced antiangiogenic therapy with antibody-collagen XVIII NC1 domain fusion proteins engineered to exploit matrix remodeling events. International Journal of Cancer, 2006, 119, 455-462.	2.3	30

#	Article	IF	Citations
73	Modulation of the p38 MAPK (mitogen-activated protein kinase) pathway through Bcr/Abl: implications in the cellular response to Ara-C. Biochemical Journal, 2005, 387, 231-238.	1.7	22
74	Replicating retroviral vectors mediating continuous production and secretion of therapeutic gene products from cancer cells. Cancer Gene Therapy, 2005, 12, 464-474.	2.2	7
75	Chronic gene delivery of interferon-inducible protein 10 through replication-competent retrovirus vectors suppresses tumor growth. Cancer Gene Therapy, 2005, 12, 900-912.	2.2	32
76	Antibody engineering: facing new challenges in cancer therapy. Acta Pharmacologica Sinica, 2005, 26, 641-648.	2.8	56
77	Establishment of an immortalized PARP-1â˜'/â˜'murine endothelial cell line: A new tool to study PARP-1 mediated endothelial cell dysfunction. Journal of Cellular Biochemistry, 2005, 94, 1163-1174.	1.2	3
78	Antibody Engineering, Virus Retargeting and Cellular Immunotherapy: One Ring to Rule Them All?. Current Gene Therapy, 2005, 5, 63-70.	0.9	10
79	Full Activation of PKB/Akt in Response to Insulin or Ionizing Radiation Is Mediated through ATM. Journal of Biological Chemistry, 2005, 280, 4029-4036.	1.6	231
80	Selection of functional human antibodies from retroviral display libraries. Nucleic Acids Research, 2005, 33, e35-e35.	6.5	34
81	Antibody-based antiangiogenic cancer therapy. Expert Opinion on Therapeutic Targets, 2005, 9, 1235-1245.	1.5	6
82	Antibodies and gene therapy: teaching old â€˜magic bulletsâ€™ new tricks. Trends in Immunology, 2004, 25, 85-91.	2.9	87
83	A novel cell binding site in the coiled-coil domain of laminin involved in capillary morphogenesis. EMBO Journal, 2003, 22, 1508-1517.	3.5	23
84	Generation of non-permissive basement membranes by anti-laminin antibody fragments produced by matrix-embedded gene-modified cells. Cancer Immunology, Immunotherapy, 2003, 52, 643-647.	2.0	18
85	Adenovirus E1a protein enhances the cytotoxic effects of the herpes thymidine kinase-ganciclovir system. Cancer Gene Therapy, 2003, 10, 152-160.	2.2	10
86	The extracellular matrix: a new turn-of-the-screw for anti-angiogenic strategies. Trends in Molecular Medicine, 2003, 9, 256-262.	3.5	21
87	Induction of Human T Lymphocyte Cytotoxicity and Inhibition of Tumor Growth by Tumor-Specific Diabody-Based Molecules Secreted from Gene-Modified Bystander Cells. Journal of Immunology, 2003, 171, 1070-1077.	0.4	55
88	Cells as Vehicles for Cancer Gene Therapy: The Missing Link Between Targeted Vectors and Systemic Delivery?. Human Gene Therapy, 2002, 13, 1263-1280.	1.4	79
89	Development of a Computer-Assisted High-Throughput Screening Platform for Anti-angiogenic Testing. Microvascular Research, 2002, 63, 335-339.	1.1	30
90	Functional improvement of antibody fragments using a novel phage coat protein III fusion system. Biochemical and Biophysical Research Communications, 2002, 298, 566-573.	1.0	26

#	Article	IF	Citations
91	Autocrine costimulation: Tumor-specific CD28-mediated costimulation of T cells by in situ production of a bifunctional B7â€“anti-CEA diabody fusion protein. Cancer Gene Therapy, 2002, 9, 275-281.	2.2	12
92	Single-chain antibody-based gene therapy: inhibition of tumor growth by in situ production of phage-derived human antibody fragments blocking functionally active sites of cell-associated matrices. Gene Therapy, 2002, 9, 1049-1053.	2.3	48
93	Tumor antigenâ€“specific induction of transcriptionally targeted retroviral vectors from chimeric immune receptorâ€“modified T cells. Nature Biotechnology, 2002, 20, 256-263.	9.4	30
94	Genetic Approaches for Antigen-Selective Cell Therapy. Current Gene Therapy, 2001, 1, 385-397.	0.9	31
95	Generation and characterization of recombinant human antibodies specific for native laminin epitopes: potential application in cancer therapy. Cancer Immunology, Immunotherapy, 2001, 50, 557-565.	2.0	28
96	Pharmacologic suppression of target cell recognition by engineered T cells expressing chimeric T-cell receptors. Cancer Gene Therapy, 2000, 7, 526-529.	2.2	10
97	Efficient Discrimination between Different Densities of Target Antigen by Tetracycline-Regulatable T Bodies. Human Gene Therapy, 1999, 10, 559-563.	1.4	20
98	Delay in resumption of the activity of tetracycline-regulatable promoter following removal of tetracycline analogues. Gene Therapy, 1997, 4, 993-997.	2.3	37
99	Antigen-specific targeting of CD28-mediated T cell co-stimulation using chimeric single-chain antibody variable fragment-CD28 receptors. European Journal of Immunology, 1996, 26, 2304-2309.	1.6	115
100	Isolation of Tumor-Derived Immunoglobulin-Idiotype from Peripheral Blood Mononuclear Cells in a B-Cell Lymphoma Patient with Minimal Disease. Journal of Immunotherapy, 1995, 17, 194-198.	1.2	1
101	4-1BB-mediated cancer immunotherapy: â€˜mission impossibleâ€™ for non-engineered IgGs?. Precision Cancer Medicine, 0, 2, 1-1.	1.8	3